A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
Trial Details
- NCT ID
- NCT07714668
- Phase
- PHASE2
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- SYS6041, bevacizumab
- SYS6041, carboplatin, bevacizumab
- paclitaxel, carboplatin, bevacizumab
- SYS6041, enlonstobart, bevacizumab
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Fully understand this clinical trial and voluntarily sign the written informed consent form
- Age ≥ 18 years old
- Histologically or cytologically confirmed high-grade serous ovarian, epithelial fallopian tube carcinoma, and primary peritoneal cancer
- Cohort A and B:subjects with platinum-sensitive disease who have received ≤2 prior lines of systemic chemotherapy and if have a BRCAm or HRD-positi…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →